IL109458A - Mixtures containing retinoic acid to inhibit the formation of NO free radicals by activated macrophages in the animal body - Google Patents

Mixtures containing retinoic acid to inhibit the formation of NO free radicals by activated macrophages in the animal body

Info

Publication number: IL109458A
Authority: IL; Israel
Prior art keywords: retinoic acid; production; tnf; atra; acid compound
Prior art date: 1993-05-17

Application number

IL10945894A

Other languages

English (en)

Hebrew (he)

Other versions

IL109458A0 (en

Original Assignee

Res Dev Foundation

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-05-17

Filing date

1994-04-27

Publication date

2001-11-25

1994-04-27 Application filed by Res Dev Foundation filed Critical Res Dev Foundation

1994-07-31 Publication of IL109458A0 publication Critical patent/IL109458A0/xx

2001-11-25 Publication of IL109458A publication Critical patent/IL109458A/en

Links

238000004519 manufacturing process Methods 0.000 title claims abstract description 32
229960001727 tretinoin Drugs 0.000 title claims abstract description 26
229930002330 retinoic acid Natural products 0.000 title claims abstract description 25
239000000203 mixture Substances 0.000 title claims abstract description 19
-1 retinoic acid compound Chemical class 0.000 title claims abstract description 17
210000002540 macrophage Anatomy 0.000 title description 36
230000005764 inhibitory process Effects 0.000 title description 14
241001465754 Metazoa Species 0.000 title description 7
230000002401 inhibitory effect Effects 0.000 claims abstract description 9
MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims description 26
230000001991 pathophysiological effect Effects 0.000 claims description 6
208000023275 Autoimmune disease Diseases 0.000 claims description 5
201000010099 disease Diseases 0.000 claims description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
230000001613 neoplastic effect Effects 0.000 claims description 4
206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
206010006895 Cachexia Diseases 0.000 claims description 2
201000005488 Capillary Leak Syndrome Diseases 0.000 claims description 2
206010063094 Cerebral malaria Diseases 0.000 claims description 2
206010040047 Sepsis Diseases 0.000 claims description 2
208000031932 Systemic capillary leak syndrome Diseases 0.000 claims description 2
201000006417 multiple sclerosis Diseases 0.000 claims description 2
201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
KGUMXGDKXYTTEY-FRCNGJHJSA-N all-trans-4-hydroxyretinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C(O)CCC1(C)C KGUMXGDKXYTTEY-FRCNGJHJSA-N 0.000 claims 2
SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 61
210000004027 cell Anatomy 0.000 description 42
101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 39
102100040247 Tumor necrosis factor Human genes 0.000 description 38
230000000694 effects Effects 0.000 description 24
230000006433 tumor necrosis factor production Effects 0.000 description 14
241001529936 Murinae Species 0.000 description 13
239000002158 endotoxin Substances 0.000 description 13
229920006008 lipopolysaccharide Polymers 0.000 description 12
238000000034 method Methods 0.000 description 11
239000006228 supernatant Substances 0.000 description 11
102000004127 Cytokines Human genes 0.000 description 9
108090000695 Cytokines Proteins 0.000 description 9
239000002609 medium Substances 0.000 description 9
210000003024 peritoneal macrophage Anatomy 0.000 description 9
230000004913 activation Effects 0.000 description 8
239000012228 culture supernatant Substances 0.000 description 8
238000002474 experimental method Methods 0.000 description 7
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 6
KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 6
238000011282 treatment Methods 0.000 description 6
108090000790 Enzymes Proteins 0.000 description 5
102000004190 Enzymes Human genes 0.000 description 5
231100000673 dose–response relationship Toxicity 0.000 description 5
230000003287 optical effect Effects 0.000 description 5
230000036962 time dependent Effects 0.000 description 5
FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 4
241000699666 Mus <mouse, genus> Species 0.000 description 4
239000005700 Putrescine Substances 0.000 description 4
108060008539 Transglutaminase Proteins 0.000 description 4
238000003556 assay Methods 0.000 description 4
230000001419 dependent effect Effects 0.000 description 4
238000000338 in vitro Methods 0.000 description 4
230000028709 inflammatory response Effects 0.000 description 4
239000003112 inhibitor Substances 0.000 description 4
SHGAZHPCJJPHSC-XFYACQKRSA-N isotretinoin Chemical compound OC(=O)/C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-XFYACQKRSA-N 0.000 description 4
230000001404 mediated effect Effects 0.000 description 4
230000003389 potentiating effect Effects 0.000 description 4
150000003254 radicals Chemical class 0.000 description 4
230000001629 suppression Effects 0.000 description 4
238000012360 testing method Methods 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
102000003601 transglutaminase Human genes 0.000 description 4
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
NCYCYZXNIZJOKI-OVSJKPMPSA-N Retinaldehyde Chemical compound O=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 description 3
238000004166 bioassay Methods 0.000 description 3
238000004113 cell culture Methods 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
230000006378 damage Effects 0.000 description 3
230000004069 differentiation Effects 0.000 description 3
230000006870 function Effects 0.000 description 3
230000012010 growth Effects 0.000 description 3
238000011534 incubation Methods 0.000 description 3
229960005280 isotretinoin Drugs 0.000 description 3
210000002864 mononuclear phagocyte Anatomy 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
235000020945 retinal Nutrition 0.000 description 3
239000011604 retinal Substances 0.000 description 3
230000028327 secretion Effects 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
230000001960 triggered effect Effects 0.000 description 3
NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 3
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
238000008157 ELISA kit Methods 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
206010061218 Inflammation Diseases 0.000 description 2
102100037850 Interferon gamma Human genes 0.000 description 2
108010074328 Interferon-gamma Proteins 0.000 description 2
108010050904 Interferons Proteins 0.000 description 2
102000014150 Interferons Human genes 0.000 description 2
108010002352 Interleukin-1 Proteins 0.000 description 2
102000000589 Interleukin-1 Human genes 0.000 description 2
108010049190 N,N-dimethylcasein Proteins 0.000 description 2
IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 2
FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
238000002835 absorbance Methods 0.000 description 2
RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
239000012190 activator Substances 0.000 description 2
230000008901 benefit Effects 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
239000013592 cell lysate Substances 0.000 description 2
230000003833 cell viability Effects 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
230000002950 deficient Effects 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
238000003306 harvesting Methods 0.000 description 2
230000006698 induction Effects 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
229940079322 interferon Drugs 0.000 description 2
230000018276 interleukin-1 production Effects 0.000 description 2
238000005259 measurement Methods 0.000 description 2
PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 2
230000004044 response Effects 0.000 description 2
229960003471 retinol Drugs 0.000 description 2
235000020944 retinol Nutrition 0.000 description 2
239000011607 retinol Substances 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
239000000243 solution Substances 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
235000019155 vitamin A Nutrition 0.000 description 2
239000011719 vitamin A Substances 0.000 description 2
229940045997 vitamin a Drugs 0.000 description 2
238000005406 washing Methods 0.000 description 2
QGVLYPPODPLXMB-UBTYZVCOSA-N (1aR,1bS,4aR,7aS,7bS,8R,9R,9aS)-4a,7b,9,9a-tetrahydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-1,1a,1b,4,4a,7a,7b,8,9,9a-decahydro-5H-cyclopropa[3,4]benzo[1,2-e]azulen-5-one Chemical compound C1=C(CO)C[C@]2(O)C(=O)C(C)=C[C@H]2[C@@]2(O)[C@H](C)[C@@H](O)[C@@]3(O)C(C)(C)[C@H]3[C@@H]21 QGVLYPPODPLXMB-UBTYZVCOSA-N 0.000 description 1
KZDCMKVLEYCGQX-UDPGNSCCSA-N 2-(diethylamino)ethyl 4-aminobenzoate;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;hydrate Chemical compound O.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 KZDCMKVLEYCGQX-UDPGNSCCSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
241000711404 Avian avulavirus 1 Species 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
108010092160 Dactinomycin Proteins 0.000 description 1
239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
102000001301 EGF receptor Human genes 0.000 description 1
108060006698 EGF receptor Proteins 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
108090000371 Esterases Proteins 0.000 description 1
229930182566 Gentamicin Natural products 0.000 description 1
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
102000006395 Globulins Human genes 0.000 description 1
108010044091 Globulins Proteins 0.000 description 1
241000282412 Homo Species 0.000 description 1
102000019223 Interleukin-1 receptor Human genes 0.000 description 1
108050006617 Interleukin-1 receptor Proteins 0.000 description 1
102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
102000004889 Interleukin-6 Human genes 0.000 description 1
108090001005 Interleukin-6 Proteins 0.000 description 1
208000012659 Joint disease Diseases 0.000 description 1
238000011050 LAL assay Methods 0.000 description 1
241000867077 Macropes Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
241000204031 Mycoplasma Species 0.000 description 1
MZNYWPRCVDMOJG-UHFFFAOYSA-N N-(1-naphthyl)ethylenediamine dihydrochloride Chemical compound [Cl-].[Cl-].C1=CC=C2C([NH2+]CC[NH3+])=CC=CC2=C1 MZNYWPRCVDMOJG-UHFFFAOYSA-N 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
101710123874 Protein-glutamine gamma-glutamyltransferase Proteins 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
102000009618 Transforming Growth Factors Human genes 0.000 description 1
108010009583 Transforming Growth Factors Proteins 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
208000009956 adenocarcinoma Diseases 0.000 description 1
230000001464 adherent effect Effects 0.000 description 1
230000004075 alteration Effects 0.000 description 1
230000003698 anagen phase Effects 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000001494 anti-thymocyte effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
230000003190 augmentative effect Effects 0.000 description 1
230000008512 biological response Effects 0.000 description 1
239000012152 bradford reagent Substances 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
235000011148 calcium chloride Nutrition 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
239000002775 capsule Substances 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
230000008859 change Effects 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
238000003501 co-culture Methods 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
239000013078 crystal Substances 0.000 description 1
238000003235 crystal violet staining Methods 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
238000002784 cytotoxicity assay Methods 0.000 description 1
231100000263 cytotoxicity test Toxicity 0.000 description 1
229960000640 dactinomycin Drugs 0.000 description 1
230000007123 defense Effects 0.000 description 1
230000001066 destructive effect Effects 0.000 description 1
XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
230000002222 downregulating effect Effects 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
230000013020 embryo development Effects 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
239000000284 extract Substances 0.000 description 1
238000013213 extrapolation Methods 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
229960002518 gentamicin Drugs 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
230000009036 growth inhibition Effects 0.000 description 1
102000057041 human TNF Human genes 0.000 description 1
230000036737 immune function Effects 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
239000000367 immunologic factor Substances 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
239000012678 infectious agent Substances 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
230000017290 interleukin-3 production Effects 0.000 description 1
229940100601 interleukin-6 Drugs 0.000 description 1
238000002955 isolation Methods 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
230000006540 mitochondrial respiration Effects 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
QGVLYPPODPLXMB-QXYKVGAMSA-N phorbol Natural products C[C@@H]1[C@@H](O)[C@]2(O)[C@H]([C@H]3C=C(CO)C[C@@]4(O)[C@H](C=C(C)C4=O)[C@@]13O)C2(C)C QGVLYPPODPLXMB-QXYKVGAMSA-N 0.000 description 1
239000002644 phorbol ester Substances 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
235000010288 sodium nitrite Nutrition 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000000527 sonication Methods 0.000 description 1
206010041823 squamous cell carcinoma Diseases 0.000 description 1
238000010186 staining Methods 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
239000000758 substrate Substances 0.000 description 1
FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
229940124530 sulfonamide Drugs 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000008399 tap water Substances 0.000 description 1
235000020679 tap water Nutrition 0.000 description 1
230000000451 tissue damage Effects 0.000 description 1
231100000827 tissue damage Toxicity 0.000 description 1
208000037816 tissue injury Diseases 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
230000005909 tumor killing Effects 0.000 description 1
102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
150000002266 vitamin A derivatives Chemical class 0.000 description 1
QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
235000005282 vitamin D3 Nutrition 0.000 description 1
239000011647 vitamin D3 Substances 0.000 description 1
229940021056 vitamin d3 Drugs 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Immunology (AREA)
Tropical Medicine & Parasitology (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Obesity (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Heart & Thoracic Surgery (AREA)
Neurosurgery (AREA)
Nutrition Science (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Physical Education & Sports Medicine (AREA)
Transplantation (AREA)
Cardiology (AREA)
Pain & Pain Management (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Steroid Compounds (AREA)
Medicines Containing Plant Substances (AREA)

IL10945894A 1993-05-17 1994-04-27 Mixtures containing retinoic acid to inhibit the formation of NO free radicals by activated macrophages in the animal body IL109458A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US08/061,471 US5457129A (en)	1993-05-17	1993-05-17	Inhibition of nitric oxide production by retinoic acid

Publications (2)

Publication Number	Publication Date
IL109458A0 IL109458A0 (en)	1994-07-31
IL109458A true IL109458A (en)	2001-11-25

Family

ID=22036008

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL10945894A IL109458A (en)	1993-05-17	1994-04-27	Mixtures containing retinoic acid to inhibit the formation of NO free radicals by activated macrophages in the animal body

Country Status (17)

Country	Link
US (2)	US5457129A (da)
EP (2)	EP0708648B1 (da)
JP (2)	JPH08510727A (da)
KR (1)	KR100345255B1 (da)
AT (1)	ATE228363T1 (da)
AU (1)	AU697072B2 (da)
CA (1)	CA2162990A1 (da)
DE (1)	DE69431801T2 (da)
DK (1)	DK0708648T3 (da)
ES (1)	ES2187522T3 (da)
IL (1)	IL109458A (da)
NZ (1)	NZ267220A (da)
PT (1)	PT708648E (da)
SA (1)	SA94150042B1 (da)
TW (1)	TW261529B (da)
WO (1)	WO1994026277A1 (da)
ZA (1)	ZA943320B (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5786332A (en) *	1995-03-06	1998-07-28	Trega Biosciences, Inc.	Cytokine restraining agents and methods of use in pathologies and conditions associated with altered cytokine levels
US5741774A (en) *	1993-11-12	1998-04-21	Trega Biosciences, Inc.	Use of a cytokine regulatory agent to treat rheumatoid arthritis
FR2735371B1 (fr) *	1995-06-19	1997-07-18	Cird Galderma	Procede pour identifier des composes antagonistes des recepteurs rars
FR2767058B1 (fr) *	1997-08-05	2000-05-05	Centre Nat Rech Scient	Utilisation d'un compose de type retinoide, notamment l'acide retinoique pour la preparation d' un medicament destine au traitement de l'obesite.
US8541469B2 (en) *	1997-08-23	2013-09-24	Glaxo Group Limited	Treatment of cell-mediated immune diseases
EP0908179A1 (en) *	1997-08-23	1999-04-14	Werner Bollag	Treatment of cell-mediated immune diseases
EP1016719A4 (en) *	1997-09-02	2000-12-13	Sumitomo Pharma	DNA PARTICIPATING IN THE REGULATION OF THE EXPRESSION OF THE PEBP2 A GENE AND THE USE THEREOF
US6596500B1 (en) *	1998-12-08	2003-07-22	The General Hospital Corporation	Binding of retinoids to M6P/IGF-II receptor
US6242473B1 (en) *	1999-01-08	2001-06-05	Maxim Pharmaceuticals, Inc.	Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
US6184246B1 (en)	1999-07-30	2001-02-06	The United States Of America As Represented By The Secretary Of Agriculture	Inhibition of cytokine production by polymethoxylated flavones
WO2001028533A2 (en) *	1999-10-19	2001-04-26	Kain Kevin C	PRODUCTS AND METHODS FOR ACTIVATING PPARη-RXR AND UP-REGULATING MONOCYTE/MACROPHAGE CD36 FOR THE TREATMENT OF MALARIA
CA2435410A1 (en) *	2001-01-26	2002-08-01	Steven Baranowitz	Systemic formulations containing beta-carotene and derivatives thereof
JP2004020220A (ja) *	2002-06-12	2004-01-22	Pioneer Electronic Corp	通信システム及び方法、通信端末装置、通信センタ装置、並びにコンピュータプログラム
US7071228B2 (en) *	2002-10-23	2006-07-04	Parks L Dean	Method of treating musculoskeletal and connective tissue inflammations
WO2006088747A2 (en) *	2005-02-14	2006-08-24	Mercer University	Serum-free reagents for the isolation, cultivation, and cryopreservation of postnatal pluripotent epiblast-like stem cells
WO2007000939A1 (ja) *	2005-06-28	2007-01-04	St. Marianna University, School Of Medicine	局所炎症治療用薬剤
WO2007104030A1 (en) *	2006-03-08	2007-09-13	Kinemed, Inc.	Retinoids and related compounds for the treatment of neuroinflammatory conditions, diseases and disorders
WO2011038537A1 (zh) *	2009-09-29	2011-04-07	上海南方基因科技有限公司	败血症以及败血症休克的预测、预防和治疗方法及试剂盒

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4200647A (en) *	1977-12-21	1980-04-29	Hoffmann-La Roche Inc.	Vitamin A compositions to treat rheumatic disease
EP0071357B1 (en) *	1981-07-14	1985-01-02	Efamol Limited	Pharmaceutical and dietary composition when used for enhancement of 1-series pg production
US5264578A (en) *	1987-03-20	1993-11-23	Allergan, Inc.	Disubstituted acetylenes bearing heterobicyclic groups and heteroaromatic or phenyl groups having retinoid like activity
WO1989006977A1 (en) *	1988-02-04	1989-08-10	Board Of Regents, The University Of Texas System	Formulation and use of retinoids in treatment of cancer and other diseases
US5157046A (en) *	1988-11-29	1992-10-20	Janssen Pharmaceutica N.V.	Method of treating epithelial disorders
US5190876A (en) *	1988-12-27	1993-03-02	Emory University	Method of modifying cellular differentiation and function and compositions therefor
JPH051100A (ja) *	1990-07-11	1993-01-08	Teijin Ltd	腫瘍壊死因子活性抑制物質及びその製造方法
GB9028123D0 (en) *	1990-12-28	1991-02-13	Erba Carlo Spa	Monoclonal antibodies against human tumor necrosis factor alpha
ES2145744T5 (es) *	1991-01-18	2008-02-01	Amgen Inc.	Procedimientos para tratar las enfermedades inducidas por el factor de necrosis tumoral.
US5795859A (en) *	1991-07-05	1998-08-18	Peptide Technology Limited	Peptide which abrogates TNF and/or LPS toxicity
AU3659293A (en) *	1992-02-11	1993-09-03	Allergan, Inc.	Heteroaryl substituted phenylethenyl compounds having retinoid-like biological activity

1993
- 1993-05-17 US US08/061,471 patent/US5457129A/en not_active Expired - Lifetime
- 1993-08-14 TW TW082106539A patent/TW261529B/zh active
1994
- 1994-04-27 IL IL10945894A patent/IL109458A/en not_active IP Right Cessation
- 1994-05-05 DE DE69431801T patent/DE69431801T2/de not_active Expired - Fee Related
- 1994-05-05 CA CA002162990A patent/CA2162990A1/en not_active Abandoned
- 1994-05-05 KR KR1019950705108A patent/KR100345255B1/ko not_active Expired - Fee Related
- 1994-05-05 WO PCT/US1994/004950 patent/WO1994026277A1/en not_active Ceased
- 1994-05-05 AU AU69441/94A patent/AU697072B2/en not_active Ceased
- 1994-05-05 ES ES94917915T patent/ES2187522T3/es not_active Expired - Lifetime
- 1994-05-05 NZ NZ267220A patent/NZ267220A/xx not_active IP Right Cessation
- 1994-05-05 JP JP6525529A patent/JPH08510727A/ja active Pending
- 1994-05-05 DK DK94917915T patent/DK0708648T3/da active
- 1994-05-05 EP EP94917915A patent/EP0708648B1/en not_active Expired - Lifetime
- 1994-05-05 PT PT94917915T patent/PT708648E/pt unknown
- 1994-05-05 AT AT94917915T patent/ATE228363T1/de not_active IP Right Cessation
- 1994-05-05 EP EP02004617A patent/EP1243264A3/en not_active Ceased
- 1994-05-16 ZA ZA943320A patent/ZA943320B/xx unknown
- 1994-06-29 SA SA94150042A patent/SA94150042B1/ar unknown
- 1994-11-30 US US08/346,626 patent/US5658949A/en not_active Expired - Fee Related
2005
- 2005-04-15 JP JP2005118118A patent/JP2005263808A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
DE69431801D1 (de)	2003-01-09
US5658949A (en)	1997-08-19
EP0708648A1 (en)	1996-05-01
DK0708648T3 (da)	2003-03-03
JP2005263808A (ja)	2005-09-29
KR960702311A (ko)	1996-04-27
NZ267220A (en)	2000-08-25
EP0708648B1 (en)	2002-11-27
WO1994026277A1 (en)	1994-11-24
SA94150042B1 (ar)	2006-06-17
KR100345255B1 (ko)	2002-11-30
IL109458A0 (en)	1994-07-31
AU697072B2 (en)	1998-09-24
PT708648E (pt)	2003-04-30
TW261529B (da)	1995-11-01
CA2162990A1 (en)	1994-11-24
US5457129A (en)	1995-10-10
ZA943320B (en)	1995-11-16
ES2187522T3 (es)	2003-06-16
EP1243264A3 (en)	2002-11-06
AU6944194A (en)	1994-12-12
EP0708648A4 (en)	1998-01-14
ATE228363T1 (de)	2002-12-15
DE69431801T2 (de)	2003-09-11
EP1243264A2 (en)	2002-09-25
JPH08510727A (ja)	1996-11-12

Legal Events

Date	Code	Title
2002-06-30	KB	Patent renewed
2004-06-20	KB	Patent renewed
2009-06-15	MM9K	Patent not in force due to non-payment of renewal fees

Publication	Publication Date	Title
US5457129A (en)	1995-10-10	Inhibition of nitric oxide production by retinoic acid
Kytikova et al.	2020	Peroxisome proliferator‐activated receptors as a therapeutic target in asthma
Sacerdote et al.	2000	In vivo and in vitro treatment with the synthetic cannabinoid CP55, 940 decreases the in vitro migration of macrophages in the rat: involvement of both CB1 and CB2 receptors
Wischmeyer et al.	2003	Glutamine attenuates tumor necrosis factor-α release and enhances heat shock protein 72 in human peripheral blood mononuclear cells
Berdyshev et al.	1997	Influence of fatty acid ethanolamides and Δ9-tetrahydrocannabinol on cytokine and arachidonate release by mononuclear cells
Jaudszus et al.	2013	Evaluation of suppressive and pro-resolving effects of EPA and DHA in human primary monocytes and T-helper cells
El-Mahmoudy et al.	2002	Thymoquinone suppresses expression of inducible nitric oxide synthase in rat macrophages
Wan et al.	2011	Leukotriene B4/antimicrobial peptide LL‐37 proinflammatory circuits are mediated by BLT1 and FPR2/ALX and are counterregulated by lipoxin A4 and resolvin E1
Pandey et al.	2012	Anti-arthritic activity of agnuside mediated through the down-regulation of inflammatory mediators and cytokines
Endres et al.	1996	Oral aspirin and ibuprofen increase cytokine‐induced synthesis of IL‐1β and of tumour necrosis factor‐αex vivo
Koppal et al.	2000	Cyclopentenone prostaglandin 15-deoxy-Δ12, 14-prostaglandin J2 acts as a general inhibitor of inflammatory responses in activated BV-2 microglial cells
Van Neerven et al.	2010	Inflammatory chemokine release of astrocytes in vitro is reduced by all‐trans retinoic acid
Jozefowski et al.	2005	Leukotrienes modulate cytokine release from dendritic cells
Chen et al.	2004	Stimulation of inducible nitric oxide synthase by monosodium urate crystals in macrophages and expression of iNOS in gouty arthritis
Oh et al.	2001	Capsazepine, a vanilloid receptor antagonist, inhibits the expression of inducible nitric oxide synthase gene in lipopolysaccharide-stimulated RAW264. 7 macrophages through the inactivation of nuclear transcription factor-kappa B
Lonardoni et al.	1994	Modulation of Leishmania (L.) amazonensis growth in cultured mouse macrophages by prostaglandins and platelet activating factor
Iuvone et al.	1997	Differential effect of L‐NAME and S‐methyl‐isothiourea on leukocyte emigration in carrageenin‐soaked sponge implants in rat
Ribardo et al.	2002	Role of melittin-like region within phospholipase A2-activating protein in biological function
Pandurangan et al.	2015	Anti-inflammatory effect of certain dimethoxy flavones
Goodwin	1986	Regulation of T cell activation by leukotriene B4
AU713504B2 (en)	1999-12-02	Inhibition of nitric oxide production by retinoic acid
Audette et al.	1990	Inhibition of leukocyte adhesion by the in vivo and in vitro administration of cannabinoids
Colak et al.	2003	Effects of trapidil on the healing of colonic anastomoses in an experimental rat model
Spagnuolo et al.	1988	Mediation of augmented monocyte adhesiveness by thromboxane
Pincus et al.	1985	Eosinophil adherence to infective larvae of Trichinella spiralis: quantification and modulation